Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41467-017-00627-z
DC Field | Value | |
---|---|---|
dc.title | Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells | |
dc.contributor.author | Fehlings, M | |
dc.contributor.author | Simoni, Y | |
dc.contributor.author | Penny, H.L | |
dc.contributor.author | Becht, E | |
dc.contributor.author | Loh, C.Y | |
dc.contributor.author | Gubin, M.M | |
dc.contributor.author | Ward, J.P | |
dc.contributor.author | Wong, S.C | |
dc.contributor.author | Schreiber, R.D | |
dc.contributor.author | Newell, E.W | |
dc.date.accessioned | 2020-10-20T10:23:47Z | |
dc.date.available | 2020-10-20T10:23:47Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Fehlings, M, Simoni, Y, Penny, H.L, Becht, E, Loh, C.Y, Gubin, M.M, Ward, J.P, Wong, S.C, Schreiber, R.D, Newell, E.W (2017). Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nature Communications 8 (1) : 562. ScholarBank@NUS Repository. https://doi.org/10.1038/s41467-017-00627-z | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/178577 | |
dc.description.abstract | The analysis of neoantigen-specific CD8+ T cells in tumour-bearing individuals is challenging due to the small pool of tumour antigen-specific T cells. Here we show that mass cytometry with multiplex combinatorial tetramer staining can identify and characterize neoantigen-specific CD8+ T cells in mice bearing T3 methylcholanthrene-induced sarcomas that are susceptible to checkpoint blockade immunotherapy. Among 81 candidate antigens tested, we identify T cells restricted to two known neoantigens simultaneously in tumours, spleens and lymph nodes in tumour-bearing mice. High-dimensional phenotypic profiling reveals that antigen-specific, tumour-infiltrating T cells are highly heterogeneous. We further show that neoantigen-specific T cells display a different phenotypic profile in mice treated with anti-CTLA-4 or anti-PD-1 immunotherapy, whereas their peripheral counterparts are not affected by the treatments. Our results provide insights into the nature of neoantigen-specific T cells and the effects of checkpoint blockade immunotherapy. © 2017 The Author(s). | |
dc.publisher | Nature Publishing Group | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | 3 methylcholanthrene | |
dc.subject | CD27 antigen | |
dc.subject | CD38 antigen | |
dc.subject | chemokine receptor CXCR3 | |
dc.subject | cytotoxic T lymphocyte antigen 4 antibody | |
dc.subject | granzyme B | |
dc.subject | hepatitis A virus cellular receptor 2 | |
dc.subject | Hermes antigen | |
dc.subject | interleukin 2 receptor alpha | |
dc.subject | interleukin 7 receptor | |
dc.subject | L selectin | |
dc.subject | monoclonal antibody | |
dc.subject | programmed death 1 antibody | |
dc.subject | programmed death 1 ligand 1 | |
dc.subject | tetramer | |
dc.subject | unclassified drug | |
dc.subject | 3 methylcholanthrene | |
dc.subject | cytotoxic T lymphocyte antigen 4 | |
dc.subject | immunological antineoplastic agent | |
dc.subject | programmed death 1 receptor | |
dc.subject | tumor antigen | |
dc.subject | antigen | |
dc.subject | cancer | |
dc.subject | cells and cell components | |
dc.subject | disease treatment | |
dc.subject | heterogeneity | |
dc.subject | immune system | |
dc.subject | phenotype | |
dc.subject | rodent | |
dc.subject | tumor | |
dc.subject | algorithm | |
dc.subject | animal cell | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | Article | |
dc.subject | CD8+ T lymphocyte | |
dc.subject | cell differentiation | |
dc.subject | cell infiltration | |
dc.subject | cell migration | |
dc.subject | comparative study | |
dc.subject | controlled study | |
dc.subject | flow cytometry | |
dc.subject | gene expression | |
dc.subject | immunocompetent cell | |
dc.subject | immunotherapy | |
dc.subject | lymph node | |
dc.subject | male | |
dc.subject | mass cytometry | |
dc.subject | melanoma | |
dc.subject | mouse | |
dc.subject | neoplasm | |
dc.subject | nonhuman | |
dc.subject | phenotype | |
dc.subject | protein expression | |
dc.subject | sarcoma | |
dc.subject | tumor immunity | |
dc.subject | upregulation | |
dc.subject | wild type | |
dc.subject | animal | |
dc.subject | antagonists and inhibitors | |
dc.subject | CD8+ T lymphocyte | |
dc.subject | chemically induced | |
dc.subject | drug effects | |
dc.subject | experimental sarcoma | |
dc.subject | immunology | |
dc.subject | immunophenotyping | |
dc.subject | immunotherapy | |
dc.subject | tumor associated leukocyte | |
dc.subject | Murinae | |
dc.subject | Mus | |
dc.subject | Animals | |
dc.subject | Antigens, Neoplasm | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | CTLA-4 Antigen | |
dc.subject | Immunophenotyping | |
dc.subject | Immunotherapy | |
dc.subject | Lymphocytes, Tumor-Infiltrating | |
dc.subject | Methylcholanthrene | |
dc.subject | Mice | |
dc.subject | Programmed Cell Death 1 Receptor | |
dc.subject | Sarcoma, Experimental | |
dc.type | Article | |
dc.contributor.department | MICROBIOLOGY AND IMMUNOLOGY | |
dc.description.doi | 10.1038/s41467-017-00627-z | |
dc.description.sourcetitle | Nature Communications | |
dc.description.volume | 8 | |
dc.description.issue | 1 | |
dc.description.page | 562 | |
dc.published.state | published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_s41467-017-00627-z.pdf | 1.5 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License